Partial responses occurred in 3 of 78 patients (importantly, all 3 had KRAS or BRAF mutations) and stable disease for more than 5 months was seen in 5 patients.36 Another phase 1 trial (NCT01392521) involving MEK (refametinib) and PI3K (copanlisib) inhibitors, refametinib in advanced solid cancers demonstrated a single patient with partial response and 9 with stable disease out of 49 enrolled patients.37 A phase 1 study of MEK (trametinib) and PI3K (buparlisib) inhibitors was conducted in 113 patients with RAS or RAF mutant non‐small cell lung, ovarian, and pancreatic cancers. This evidence concerns the gene MAP2K7 and familial pancreatic carcinoma.